Drugs / SS109
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05651061 | Dec 2022 → Mar 2023 | factor VII deficiency, hemophilia A, hemophilia B | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06010953 | Oct 2023 → May 2024 | hemophilia A, hemophilia B | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SS109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06010953 ↗ |